Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Karen M. Anderson Sells 6,471 Shares of Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 6,471 shares of Centessa Pharmaceuticals stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $16.86, for a total value of $109,101.06. Following the completion of the sale, the insider now directly owns 54,322 shares in the company, valued at approximately $915,868.92. This represents a 10.64 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $16.41 on Wednesday. The business’s 50 day moving average price is $16.75 and its two-hundred day moving average price is $15.27. The company has a market cap of $2.16 billion, a PE ratio of -10.73 and a beta of 1.53. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15. Centessa Pharmaceuticals plc has a twelve month low of $7.38 and a twelve month high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. On average, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 47.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC grew its position in shares of Centessa Pharmaceuticals by 29.1% in the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock valued at $64,000 after purchasing an additional 865 shares during the last quarter. Atria Investments Inc grew its position in shares of Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after purchasing an additional 1,116 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 39.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock valued at $317,000 after purchasing an additional 5,316 shares during the last quarter. Finally, Walleye Capital LLC acquired a new position in shares of Centessa Pharmaceuticals in the third quarter valued at approximately $187,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on CNTA. TD Cowen began coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They issued a “buy” rating on the stock. Guggenheim lifted their target price on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.